Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Trilostane
CP Pharma Handelsgesellschaft mbH
QH02CA01
Trilostane
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Anti Hormone Agent
Authorized
2023-09-18
Issued: September 2023 AN: 02722/2021 Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Trilotab 30 mg chewable tablets for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Trilostane 30 mg 3. PHARMACEUTICAL FORM Tablet. Off-white to light brown with brown spots, round and convex tablet with a cross- shaped break line on one side. Tablets can be divided into 2 or 4 equal parts. 4. CLINICAL INFORMATION 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing’s disease and syndrome). 4.3 CONTRAINDICATIONS Do not use in animals suffering from primary hepatic disease and/or renal insufficiency. Do not use in cases of hypersensitivity to the active substance or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES An accurate diagnosis of hyperadrenocorticism is essential. Where there is no apparent response to treatment, the diagnosis should be re- evaluated. Dose increases may be necessary. Veterinarians should be aware that dogs with hyperadrenocorticism are at increased risk of pancreatitis. This risk may not diminish following treatment with trilostane. Issued: September 2023 AN: 02722/2021 Page 2 of 7 4.5 SPECIAL PRECAUTIONS FOR USE i) Special precautions for safe use in animals: As the majority of cases of hyperadrenocorticism are diagnosed in dogs between the ages of 10-15 years, other pathological processes are frequently present. It is particularly important to screen cases for primary hepatic disease and renal insufficiency as the product is contraindicated in these cases. Subsequent close monitoring during treatment should be carried out. Particular attention should be paid to liver enzymes, electrolytes, urea and creatinine. The presence of diabetes mellitus and hyperadrenocorticism together requires specific monitoring. If a dog has previously been treated with mitotane, its adrenal function Read the complete document